Core Insights - Indaptus Therapeutics has secured new patent approvals in China, Japan, and Israel for its Decoy platform, which targets Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) [1][2][5] - The Decoy platform utilizes attenuated and killed bacteria to stimulate the immune system, showing significant activity against chronic HBV and HIV in preclinical studies [4][8] - The company is advancing its Decoy20 candidate in a Phase 1 clinical trial in the U.S. for patients with advanced cancers, further establishing its position in immunotherapy innovation [5][6] Industry Context - Chronic HBV infections are a major health concern, particularly in Asia, with approximately 87 million people affected in China and 1.1 to 1.2 million in Japan [7] - In 2022, HBV was responsible for an estimated 1.1 million deaths globally, primarily due to complications like cirrhosis and liver cancer [7] - The need for new therapies is urgent, as existing treatments do not sufficiently improve long-term outcomes for chronic infections [3][6]
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments